论文部分内容阅读
目的探讨胸腺肽α1辅助三维适形放射治疗中晚期食管癌的临床效果。方法选择2014年1月—2015年1月收治的90例中晚期食管癌患者作为研究对象,随机分为对照组和观察组各45例。对照组采用三维适形放射治疗,观察组在对照组基础上加用胸腺肽α1治疗。记录并比较两组临床疗效及治疗前后患者免疫功能变化情况。计量资料采用t检验,计数资料采用χ2检验,P<0.05为差异有统计学意义。结果观察组控制率为80.00%,优于对照组的60.00%,差异有统计学意义(P<0.05)。治疗后,观察组CD4+、CD8+及CD4+/CD8+水平分别为(39.95±4.02)%、(20.13±3.47)%、(1.86±0.36),均优于对照组的(28.74±4.86)%、(26.52±4.20)%、(0.97±0.28),差异均有统计学意义(均P<0.05)。结论胸腺肽α1辅助三维适形放射治疗中晚期食管癌效果显著。
Objective To investigate the clinical effect of thymosin α1-assisted three-dimensional conformal radiotherapy on advanced esophageal cancer. Methods From January 2014 to January 2015, 90 patients with advanced esophageal cancer admitted to our hospital were randomly divided into control group and observation group of 45 cases. Control group using three-dimensional conformal radiotherapy, the observation group on the basis of the control group with thymosin α1 treatment. Record and compare the two groups of clinical efficacy and changes in patients with immune function before and after treatment. Measurement data using t test, count data using χ2 test, P <0.05 for the difference was statistically significant. Results The control rate of the observation group was 80.00%, which was higher than that of the control group (60.00%), the difference was statistically significant (P <0.05). After treatment, the levels of CD4 +, CD8 + and CD4 + / CD8 + in the observation group were (39.95 ± 4.02)% and (20.13 ± 3.47)% and (1.86 ± 0.36), respectively, which were significantly higher than those in the control group (28.74 ± 4.86% and 26.52 ± 4.20)%, (0.97 ± 0.28), respectively, with significant difference (all P <0.05). Conclusion Thymosin α1-assisted three-dimensional conformal radiotherapy has a significant effect on advanced esophageal cancer.